Drug Type Trispecific T-cell engager (TriTE) |
Synonyms- |
Target |
Mechanism CD28 modulators(T-cell-specific surface glycoprotein CD28 modulators), PDL1 modulators(Programmed death-ligand 1 modulators), PDL2 inhibitors(Programmed cell death 1 ligand 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | 07 Nov 2022 |